- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Grants Expanded Approval of Siemens Healthineers Mammography Platform for Digital Breast Tomosynthesis
The inclusion of the 3D imaging technology PlatinumTomo in the Mammomat B.brilliant device reportedly enables clinicians to obtain 50-degree 3D images in less than five seconds.
Offering a variety of new features for improved efficiency and enhanced 3D breast imaging, the mammography platform Mammomat B.brilliant has garnered an expanded approval from the Food and Drug Administration (FDA).
Building upon the 50-degree wide-angle technology of its existing 3D mammography systems, Siemens Healthineers says the expanded approval for the device includes PlatinumTomo, which reduces blurring that commonly occurs with 3D imaging and allows one to obtain 50-degree 3D images in less than five seconds.
New features with the Mammomat B.brilliant platform include PlatinumTomo, which enables five-second acquisition of 50-degree 3D images, and UltraHD technology, which reduces metal artifacts and provides enhanced visualization of calcifications, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
Other new features with the Mammomat B.brilliant platform include a new X-ray tube, which includes adaptation of the flying focal spot technology from the company’s computed tomography (CT) scanners, according to Siemens Healthineers, the manufacturer of the Mammomat B.brilliant Device.
The company pointed out that the expanded approval also includes UltraHD technology for image reconstruction that facilitates enhanced calcification visualization, reduced metal artifacts and the availability of synthetic 2D images without exposing patients to additional radiation.
“This revolutionary system not only provides health-care institutions with significantly improved diagnostic capabilities but also addresses the critical need for patient and technologist comfort in breast cancer screening,” added Niral Patel, the vice president of X-ray products at Siemens Healthineers North America.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
